A chalcone derivative AD-021 inhibits kidney fibrosis in a mouse model of high fat diet/streptozotocin -induced diabetic nephropathy
Keywords:
Diabetic nephropathy, chalcone derivatives, kidney fibrosis, diabetic mellitusAbstract
Diabetic nephropathy (DN) is the most prevalent microvascular disorder in diabetes mellitus and plays an integral role in the aggravation of renal injury and fibrosis, which currently lacks effective treatments. The chalcone derivative AD-021 is a small synthetic molecule recently identified for treating kidney disease. In this study, we evaluated effects of AD-021 on kidney function and kidney fibrosis in a high-fat diet (HFD) combined with streptozotocin (STZ)-induced DN in mice. Mice were treated with intraperitoneal administration of AD-021 (50 mg/kg/day) for 12 weeks. Determination of fasting blood glucose (FBG), renal function-related albumin/creatinine ratio, and urine volume in mice and histopathological section analysis of collagen deposition in kidney tissue were performed. Moreover, western blot analysis was used to investigate the expressions of TGF-β1 and profibrotic-related proteins. We found that administration of AD-021 (50 mg/kg/day) reduced FBG, albumin/creatinine ratio, urine volume and collagen deposition in kidney tissue of DN mice. Furthermore, AD-021 significantly inhibited expression of TGF-β1 and fibronectin, and alleviated loss of E-cadherin protein expression in HFD/STZ-induced DN mice. These data suggest that AD-021 has the potential as a nephroprotective agent in DN patients.
References
Reutens, A.T., Epidemiology of diabetic kidney disease. Med Clin North Am, 2013. 97(1): p. 1-18.
Park, C.W., Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J, 2014. 38(4): p. 252-60.
Vallon, V. and R. Komers, Pathophysiology of the diabetic kidney. Compr Physiol, 2011. 1(3): p. 1175-232.
Lin, Y.C., et al., Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc, 2018. 117(8): p. 662-675.
Loeffler, I. and G. Wolf, Mechanisms of Interstitial Fibrosis in Diabetic Nephropathy, in Diabetic Nephropathy: Pathophysiology and Clinical Aspects, J.J. Roelofs and L. Vogt, Editors. 2019, Springer International Publishing: Cham. p. 227-251.
McVicker, B.L. and R.G. Bennett, Novel Anti-fibrotic Therapies. Front Pharmacol, 2017. 8: p. 318.
Mahapatra, D.K., S.K. Bharti, and V. Asati, Chalcone Derivatives: Anti-inflammatory Potential and Molecular Targets Perspectives. Curr Top Med Chem, 2017. 17(28): p. 3146-3169.
Hsieh, C.T., et al., Synthesis of chalcone derivatives as potential anti-diabetic agents. Bioorg Med Chem Lett, 2012. 22(12): p. 3912-5.
Poolsri, W., et al., Discovery of a chalcone derivative as an anti-fibrotic agent targeting transforming growth factor-beta1 signaling: Potential therapy of renal fibrosis. Biomed Pharmacother, 2023. 165: p. 115098.
Ahmed, F., et al., Meprin-beta activity modulates the beta-catalytic subunit of protein kinase A in ischemia-reperfusion-induced acute kidney injury. Am J Physiol Renal Physiol, 2020. 318(5): p. F1147-F1159.
Tang, F., et al., Effect of echinacoside on kidney fibrosis by inhibition of TGF-beta1/Smads signaling pathway in the db/db mice model of diabetic nephropathy. Drug Des Devel Ther, 2017. 11: p. 2813-2826.
Rudrapal, M., et al., Chalcone Scaffolds, Bioprecursors of Flavonoids: Chemistry, Bioactivities, and Pharmacokinetics. Molecules, 2021. 26(23).
Rocha, S., et al., A Systematic Review on Anti-diabetic Properties of Chalcones. Curr Med Chem, 2020. 27(14): p. 2257-2321.
Balu, P., J.S. Jas, and M. Govindaraj, Design and evaluation of chalconeimine derivatives as alpha-amylase inhibitors. Bioinformation, 2019. 15(7): p. 523-529.
Xiao, P.J., et al., Chalcone-1-Deoxynojirimycin Heterozygote Reduced the Blood Glucose Concentration and Alleviated the Adverse Symptoms and Intestinal Flora Disorder of Diabetes Mellitus Rats. Molecules, 2022. 27(21).
Li, C., et al., Discovery of a chalcone derivative as potent necroptosis inhibitor for the treatment of acute kidney injury. Clin Exp Pharmacol Physiol, 2022. 49(8): p. 824-835.
Yang, R.Z., et al., Alanine aminotransferase isoenzymes: molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity. Hepatology, 2009. 49(2): p. 598-607.
Adelusi, T., et al., Novel Chalcone BDD-39 Mitigated Diabetic Nephropathy through the Activation of Nrf2/ARE Signaling. Curr Mol Pharmacol, 2022. 15(4): p. 658-675.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Journal of Physiological and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
